VectivBio (VECT) Competitors $16.85 0.00 (0.00%) (As of 12/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrends VECT vs. NAMS, IDYA, CNTA, RXRX, IBRX, APGE, WVE, AKRO, MIRM, and TARSShould you be buying VectivBio stock or one of its competitors? The main competitors of VectivBio include NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Centessa Pharmaceuticals (CNTA), Recursion Pharmaceuticals (RXRX), ImmunityBio (IBRX), Apogee Therapeutics (APGE), Wave Life Sciences (WVE), Akero Therapeutics (AKRO), Mirum Pharmaceuticals (MIRM), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. VectivBio vs. NewAmsterdam Pharma IDEAYA Biosciences Centessa Pharmaceuticals Recursion Pharmaceuticals ImmunityBio Apogee Therapeutics Wave Life Sciences Akero Therapeutics Mirum Pharmaceuticals Tarsus Pharmaceuticals NewAmsterdam Pharma (NASDAQ:NAMS) and VectivBio (NASDAQ:VECT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations. Do analysts rate NAMS or VECT? NewAmsterdam Pharma presently has a consensus target price of $36.20, indicating a potential upside of 41.96%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe NewAmsterdam Pharma is more favorable than VectivBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is NAMS or VECT more profitable? Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A VectivBio N/A N/A N/A Do institutionals and insiders believe in NAMS or VECT? 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 19.5% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 9.7% of VectivBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in NAMS or VECT? NewAmsterdam Pharma received 11 more outperform votes than VectivBio when rated by MarketBeat users. Likewise, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 43.48% of users gave VectivBio an outperform vote. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes21100.00% Underperform VotesNo VotesVectivBioOutperform Votes1043.48% Underperform Votes1356.52% Which has better earnings and valuation, NAMS or VECT? VectivBio has lower revenue, but higher earnings than NewAmsterdam Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$33.59M70.13-$176.94MN/AN/AVectivBio$27.34M20.97-$93.74MN/AN/A Does the media prefer NAMS or VECT? In the previous week, NewAmsterdam Pharma had 19 more articles in the media than VectivBio. MarketBeat recorded 19 mentions for NewAmsterdam Pharma and 0 mentions for VectivBio. NewAmsterdam Pharma's average media sentiment score of 0.77 beat VectivBio's score of 0.00 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Overall Sentiment NewAmsterdam Pharma Positive VectivBio Neutral Which has more risk & volatility, NAMS or VECT? NewAmsterdam Pharma has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, VectivBio has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. SummaryNewAmsterdam Pharma beats VectivBio on 11 of the 13 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get VectivBio News Delivered to You Automatically Sign up to receive the latest news and ratings for VECT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VECT vs. The Competition Export to ExcelMetricVectivBioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$573.24M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E RatioN/A46.7390.0517.20Price / Sales20.97415.011,117.09117.04Price / CashN/A182.1043.1037.85Price / Book2.693.894.784.78Net Income-$93.74M-$42.21M$120.31M$225.60M7 Day PerformanceN/A-2.15%-1.92%-1.23%1 Month PerformanceN/A1.73%13.65%0.46%1 Year PerformanceN/A16.36%28.34%15.24% VectivBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030NAMSNewAmsterdam Pharma2.8011 of 5 stars$24.71+0.1%$36.20+46.5%+127.9%$2.28B$33.59M0.0057Insider TradeAnalyst RevisionGap DownIDYAIDEAYA Biosciences4.3252 of 5 stars$26.05+3.4%$53.67+106.0%-24.5%$2.25B$3.92M-10.8180Analyst ForecastCNTACentessa Pharmaceuticals2.8492 of 5 stars$16.75+1.1%$25.83+54.2%+131.3%$2.21B$6.85M-10.8372Insider TradeRXRXRecursion Pharmaceuticals2.4112 of 5 stars$7.44+7.1%$9.25+24.3%-38.7%$2.13B$44.58M-4.85400News CoverageGap UpHigh Trading VolumeIBRXImmunityBio2.1284 of 5 stars$3.06+6.6%$17.38+467.8%-35.8%$2.13B$7.33M-3.36590Analyst ForecastHigh Trading VolumeAPGEApogee Therapeutics2.6239 of 5 stars$47.21+6.1%$83.88+77.7%+86.7%$2.13BN/A-18.3991Positive NewsWVEWave Life Sciences4.8801 of 5 stars$13.45+0.1%$22.22+65.2%+168.6%$2.05B$53.61M-12.12240AKROAkero Therapeutics4.0824 of 5 stars$29.23+1.2%$46.83+60.2%+31.5%$2.04BN/A-7.7030Insider TradeMIRMMirum Pharmaceuticals4.0875 of 5 stars$42.39-0.1%$57.73+36.2%+33.5%$2.03B$307.03M-21.01140Positive NewsTARSTarsus Pharmaceuticals0.3248 of 5 stars$51.73-1.5%$54.20+4.8%+163.2%$1.98B$17.45M-13.7850Gap Down Related Companies and Tools Related Companies NAMS Alternatives IDYA Alternatives CNTA Alternatives RXRX Alternatives IBRX Alternatives APGE Alternatives WVE Alternatives AKRO Alternatives MIRM Alternatives TARS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VECT) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VectivBio Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share VectivBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
